Table 2 Univariate and multivariate analyses of clinical variables and response to EGFR TKIs.

Age (< 60/ ≥ 60)

1.42 (0.65–3.12)

0.38

Sex (male/female)

1.34 (0.61–2.97)

0.47

ECOG PS (≥ 2/0–1)

2.12 (0.83–5.40)

0.12

Smoking (current-former/never)

2.55 (1.05–6.23)

0.04*

2.14 (0.83–5.54)

0.12

Histology (non-ADC/ADC)

Not estimated

1

Stage at diagnosis (M1/M0)

8.03 (1.07–60.42)

0.04*

5.01 (0.65–38.91)

0.12

Curative surgery (no/yes)

3.25 (0.75–14.17)

0.12

Number of metastatic sites (≥ 3/1–2)

0.95 (0.40–2.26)

0.91

Brain metastasis (yes/no)

1.63 (0.70–3.81)

0.26

Liver metastasis (yes/no)

0.56 (0.13–2.48)

0.45

EGFR subtype (others/common)

5.60 (2.14–14.69)

 < 0.001*

6.83 (2.36–19.80)

 < 0.001*

Common EGFR subtype (Del19/L858R)

0.78 (0.31–1.94)

0.59

Line of TKI (first/later)

0.88 (0.39–1.96)

0.75

Generation of TKI (first/second)

0.40 (0.11–1.53)

0.18

First generation of TKI (gefitinib/erlotinib)

1.23 (0.51–2.98)

0.64

Age (< 60/ ≥ 60)

1.78 (0.73–4.38)

0.21

Sex (male/female)

1.65 (0.66–4.13)

0.28

ECOG PS (≥ 2/0–1)

4.50 (1.19–16.98)

0.03*

7.39 (1.16–47.16)

0.04*

Smoking (current-former/never)

2.53 (0.87–7.35)

0.09

2.38 (0.55–10.33)

0.25

Histology (non-ADC/ADC)

Not estimated

1

Stage at diagnosis (M1/M0)

15.15 (1.93–118.86)

0.01*

61.45 (1.29–NE)

0.04*

Curative surgery (no/yes)

6.35 (1.38–29.32)

0.02*

0.30 (0.02–5.55)

0.42

Number of metastatic sites (≥ 3/1–2)

4.72 (1.38–16.10)

0.01*

4.05 (0.54–30.53)

0.18

Brain metastasis (yes/no)

2.56 (0.90–7.25)

0.08

1.92 (0.42–8.67)

0.40

Liver metastasis (yes/no)

0.74 (0.14–3.93)

0.73

EGFR subtype (others/common)

8.13 (1.97–33.64)

0.004*

16.84 (1.66–171.45)

0.02*

Common EGFR subtype (Del19/L858R)

0.85 (0.31–2.33)

0.75

Line of TKI (first/later)

0.52 (0.20–1.33)

0.17

Generation of TKI (first/second)

Not estimated

1

First generation of TKI (gefitinib/erlotinib)

1.76 (0.67–4.66)

0.26